Fig. 8
Preliminary clinical trial results. (A) Chart showing initial tumor volumes when patients arrived for diagnosis (black bars), and at terminal point of trial (white bars). Disease progress is labeled via RECIST criteria as progressive disease (PD, > 20% increase in tumor size) or partial response (PR, > 30% reduction in tumor size, but not complete disappearance). (B) Photograph of patient 4 (see Supplemental Tables S4-S5 and Figures S3-S4) at the time of pre-enrollment, (C) photograph of the same patient following 14 days of treatment with trametinib, (D) photograph of the same patient at 56 days, upon exiting the trial. (E) CT bone window slice of patient 3 showing osseous tumor invasion at initial diagnosis, and (F) corresponding CT bone window slice of following 4 weeks of treatment with trametinib, exhibiting tumor size reduction and osseous regeneration.
